Dun forget u juz my urself a big joke here....remember What u say...already told you guys that it is inaccurate news that Inix submitted the application to NPRA but you guys don't believe me. Inix just wants to goreng up the share price thats all.
.@536826 .So who is telling the lie?? U or the edge 20/01/2021 8:07 PM
You re telling lies...you re the mother of CON? Why..... You talk bad mouth and full of hatred to INiX may be.. you lost your rationality out of hatred to the stock....lol
.To naysayers whom love to enlarged or altered beyond normal proportions statements or info and in doing so blatantly exaggerated well beyond reasonable rationality and clearly with regards to this stock which may tarnished or gravely mislead the name and stock, i believe INIX legal will take it very seriously...so as to protect and safeguard shareholders and company interest.....within.
PRESS RELEASE IMMEDIATE RELEASE Inix clarifies media’s report of “unsubmitted” application to NPRA ● The submission has been made and received by NPRA on 11 January 2021 ● Inix is currently in the midst of providing additional information to the relevant authority
KUALA LUMPUR, 20th JANUARY 2021 – Inix Technologies Holdings Bhd (“Inix” or “Group” or “Company”) would like to clarify a news report titled “INIX Technologies’ application to supply Covid-19 vaccines yet to be received by NPRA” by The Edge Media Group.
The Group, via its subsidiary, has submitted its application, for the registration with the Malaysian National Pharmaceutical Regulatory Agency (NPRA) under the Ministry of Health in relation to its agreement to source vaccines for COVID-19, from China. Its suppliers for the COVID-19 vaccines are Sinovac Biotech Co Ltd, CanSino Biologic Inc and Sinopharm China / National Biotech Group Co Ltd.
*The application was made by INIX and received by NPRA on 11 January 2021. The authority has since requested additional information in relation to the application.*
Currently, the Group is in the midst of preparing the additional information requested by NPRA. “We hope that this would clear the air and that our media friends would seek us for clarification in future,” the Company said.
The management is planning to have a total of 14 production lines within the next 12 months. INIX will have the capacity to produce 364,000,000 gloves per quarter. Top Glove’s revenue per glove is RM 0.21. Assuming INIX’s revenue is RM 0.18. The production lines will contribute a revenue of RM 33,415,200 per quarter and a PAT rate of 40%, it would bring in a PAT of RM 13,366,080. That would mean a PAT of RM 53,464,320 per annum. At the price of RM 0.365 per share, INIX is trading at a forward PE of 3, making it the cheapest glove stock trading on KLSE. This analysis doesn’t include the future prospect of INIX’s vaccine venture and the increase of ASP for gloves. INIX is the only stock that is doing both vaccine and glove.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
STEADYBOMBIBI85
1,077 posts
Posted by STEADYBOMBIBI85 > 2021-01-20 19:48 | Report Abuse
Lol im not even in this stock what you talking about...